Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein mono-ADP-ribosyltransferase PARP8 (PARP8) is an enzyme belonging to the poly(ADP-ribose) polymerase (PARP) family, specifically classified as a mono-ADP-ribosyltransferase (MART). Unlike the best-known PARP family members (such as PARP1 and PARP2) that play established roles in DNA repair, PARP8's physiological function is less well characterized. PARP8 localizes predominantly to the nuclear envelope in mammalian cells. Knockdown studies suggest it is critical for the organization and integrity of the nuclear envelope, influencing nuclear morphology and potentially nuclear envelope biogenesis[2][4]. Additionally, there is evidence for its involvement in the assembly or maintenance of membranous organelles[3][4]. PARP8 uses NAD+ as its substrate, modifying target proteins by the addition of ADP-ribose moieties (a process known as mono-ADP-ribosylation)[3][5]. As of now, PARP8 is not implicated in major human diseases nor targeted by therapeutic drugs, and its direct roles in signal transduction, DNA repair, apoptosis, or other cell signaling pathways remain underexplored.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein mono-ADP-ribosyltransferase PARP8 (PARP8).